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Abstract
Background: Temporal lobe epilepsy (TLE) is a common form of focal epilepsy. Serum biomarkers to predict
cognitive performance in TLE patients without psychiatric comorbidities and the link with gray matter (GM)
atrophy have not been fully explored.
Methods: Thirty-four patients with TLE and 34 sex - and age-matched controls were enrolled for standardized
cognitive tests, neuroimaging studies as well as measurements of serum levels of heat shock protein 70 (HSP70),
S100ß protein (S100ßP), neuronal specific enolase (NSE), plasma nuclear and mitochondrial DNA levels.
Results: Compared with the controls, the patients with TLE had poorer cognitive performances and higher HSP70
and S100ßP levels (p < 0.01). The patients with higher frequencies of seizures had higher levels of HSP70, NSE and
S100ßP (p < 0.01). Serum HSP70 level correlated positively with duration of epilepsy (s = 0.413, p < 0.01), and
inversely with memory scores in the late registration (s = −0.276, p = 0.01) and early recall score (s = −0.304, p =
0.007). Compared with the controls, gray matter atrophy in the hippocampal and parahippocampal areas, putamen,
thalamus and supplementary motor areas were found in the patient group. The HSP70 levels showed an inverse
correlation with hippocampal volume (R square = 0.22, p = 0.007) after controlling for the effect of age.
Conclusions: Our results suggest that serum biomarkers were predictive of higher frequencies of seizures in the
TLE group. HSP70 may be considered to be a stress biomarker in patients with TLE in that it correlated inversely
with memory scores and hippocampal volume. In addition, the symmetric extratemporal atrophic patterns may be
related to damage of neuronal networks and epileptogenesis in TLE.
Keywords: Biomarkers, Neuropsychological performances, Temporal lobe epilepsy, Gray matter atrophy, Heat shock
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Background
Temporal lobe epilepsy (TLE) represents the most com-
mon and likely to be medically refractory focal epilepsy
in adults, with an estimated prevalence of 40% among
epilepsy patients [1]. Although epileptic focus in most
cases of TLE originates from the temporal lobe and par-
ticularly the hippocampus, virtually all patients develop
complex partial seizures with or without secondary gen-
eralization [2]. Antiepileptic drugs (AEDs) are usually
successful in controlling secondarily generalized sei-
zures, however as many as 30% to 40% of TLE patients
still have seizures despite receiving appropriate medical
management [3]. Those with pharmacoresistant TLE
often require surgical treatment [4] along with lifelong
AED therapy, and are associated with greater comorbid-
ities and functional disabilities [5].
Proper selection of serological biomarkers, for exam-
ple prolactin [6], can extend the diagnostic repertoire
of epileptic seizures in the clinical setting. There were
studies exploring the relationship between serum
S100ß protein (S100ßP), neuron specific enolase (NSE)
and heat shock protein 70 (HSP70) in Alzheimer
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dementia [7], status epilepticus [8] and epilepsy syn-
drome [9]. Upregulation of HSP70 protects against
intracellular amyloid toxicity by rescuing proteasomal
activity [7]. Pathology study in sudden and unexpected
death in epilepsy suggested that HSP70 overexpression
indicates acute neuronal injury occurring in the ante-
mortem stage [9]. Elevated serum NSE has been
reported in patients with status epilepticus, complex
partial status, in addition to TLE [8,10,11]. In TLE, a
few studies have suggested that serum S100ßP [12,13],
NSE [14] or HSP70 [15-17] may be useful biomarkers
for central nervous system damage. However, little
data exists with regards to these biomarkers and cogni-
tive performances in TLE. Elevation of plasma nuclear
and mitochondrial DNA has been considered to be the
consequence of neuronal cell death in the brain par-
enchyma, and has been linked with poor outcomes in
bacterial meningitis and ischemic stroke [18,19]. How-
ever, whether these two biomarkers are also associated
with poor cognitive performances in TLE has not been
reported before.
TLE can be a progressive disorder, potentially result-
ing in structural damage and a decline of cognitive
abilities over time [20]. Impairment in cognitive per-
formance beyond the memory domain has been fre-
quently reported in patients with TLE [21,22], and a
link between cognitive deficits with structural changes
has been proposed. One meta-analysis reviewed the
voxel-based morphometry (VBM) results in patients
with TLE [23] and showed extratemporal gray matter
(GM) atrophy. Although GM atrophy in TLE has been
reported to be greater on the ipsilateral side in terms
of epileptogenesis, the correlation accounting for cog-
nitive deficits and the relationship with biomarkers
have not been fully explored.
Recent studies have highlighted that self-propagating
seizure activities in TLE may result in dysregulated
inflammation, blood brain barrier damage and neuronal
damage [24]. Since HSP70, S100ßP, NSE, as well as
plasma nuclear and mitochondrial DNA levels have been
shown to reflect central nervous system damage, the pre-
sent study hypothesized that these biomarkers may be of
prognostic value in TLE patients from the cognitive
aspect. We attempted to validate our hypothesis by mea-
suring these biomarkers in TLE patients compared with
age-and sex-matched controls, and compared the cogni-
tive performances and structural imaging analysis using
VBM in the GM areas. Furthermore, correlations
between the biomarkers with duration of epilepsy, fre-
quency of seizures and GM volume in the TLE group
were examined in an attempt to understand the relation-
ship between these biomarkers in predicting the severity
of TLE and related neuronal damage.
Methods
Study design
This was a single center, age-and sex-matched cross-
sectional study which was approved by the Institutional
Review Board of Chang Gung Memorial Hospital and
complied with the ethical standards established in the
Declaration of Helsinki. The experiments were underta-
ken with the written, informed consent of each subject
and their caregiver (when appropriate).
Patient enrolment
This study was initiated at the epilepsy outpatient clinic
of Kaohsiung Chang Gung Memorial Hospital in 2009.
Patients followed up as the epilepsy cohort [25] all
underwent an extensive investigation including clinical
history, comprehensive neurologic examination, interic-
tal EEG and routine visual MRI analysis, the protocol of
which included T1 and T2 sequences in axial and coro-
nal planes.
The clinical diagnosis of TLE was based on the Interna-
tional League Against Epilepsy criteria (1997) as follows:
(1) seizure semiology consistent with TLE, with abdom-
inal, epigastric, psychic, or autonomic auras, followed by
behavioral arrest, progressive alteration of consciousness,
oroalimentary, and manual automatisms; (2) mesial and/
or anterior temporal interictal spikes from video-electro-
encephalography (EEG) or bilateral sphenoidal EEG; and
(3) no lesions other than increased T2 signal and/or atro-
phy in hippocampal formation identified by MRI.
Because it was not possible to combine all the influen-
tial factors in the TLE group to produce a uniform popu-
lation, we only included non-surgical patients. By family
history and past medical history review, none of our
study patient had family trait or childhood febrile seizure
history. Additional exclusion criteria in this study
included a known history of mental retardation and a
psychiatric comorbidity that prevented either a neuropsy-
chiatric interview or neuroimaging. We also excluded
patients with any of the following: (1) medication history
of psychoactive or central nervous system depressant
drugs; and (2) abnormal liver or renal functions. These
exclusion criteria were added to avoid the confounding
effects of medication and physical disorders on the cogni-
tive test results.
After screening our TLE cohort [25], 34 patients (15
males and 19 females) fulfilled the inclusion and exclu-
sion criteria, agreed to participate in the study, and
completed it. Data for the age at onset, duration of epi-
lepsy, average seizure frequency per month during the
previous year, and numbers of AED were analyzed.
According to the seizure frequency, patients with two or
fewer seizures per month were classified as Group 1,
and patients with more than two seizures per month as
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Group 2. Furthermore, 34 age-and sex-matched healthy
subjects from the normative database were used as con-
trols for the biomarkers, neuropsychological testing and
MRI comparison. The age of each control subject was
within 1 year of the matched TLE patient. None of the
control subjects had a history of neurologic or neurop-
sychiatric disorders, and all had normal MRI and basic
blood test results (liver and renal function tests, electro-
lytes, and complete blood cell counts).
Analysis of serological biomarkers
Blood samples were taken between 8 and 10 am after
overnight fasting for the analysis of serum levels of
HSP70, NSE and S100ßP. Liver and renal function tests,
electrolytes, and complete blood cell counts were also
analyzed by the central laboratory of Chang Gung Mem-
orial Hospital-Kaohsiung.
For each patient, 5 ml of peripheral venous blood was
collected into a serum separating tube. Plasma was pre-
pared using EDTA-containing tubes and centrifugation at
3,000 rpm for 10 minutes, isolated, and immediately
stored at −80 C in multiple aliquots. Serum HSP70, NSE
and S100ßP levels were measured using an enzyme-linked
immunosorbent assay (ELISA) kit (HSP70: EKS-750,
Assay Design, San Francisco, CA, USA.; NSE: TM E-4700,
Labor Diagnostika Nord, Nordhorn, Germany; S100ßP:
RD192090100R, BioVendor, Brno, Czech Republic). In the
ELISA, the samples were incubated in multiwell plates
that had been coated with markers specific for anti-
HSP70, anti-NSE, and anti-S100ßP antibodies. The ELISA
procedures followed the manufacturer’s protocols. The
degrees of enzymatic turnover of the substrate were deter-
mined by dual wavelength absorbance measurements at
450 nm using a multiscan spectrum reader (Thermo
Scientific, Miami, FL, USA). The antigen standards were
used to plot a standard curve of absorbance versus antigen
concentration from which the antigen concentrations in
the unknowns were calculated.
Analysis of plasma nuclear and mitochondrial DNA levels
To evaluate the neuronal cell damage, we detected the
released specific mitochondrial DNA (ND2 gene) and
nuclear DNA (beta globulin gene) levels in plasma by real-
time quantitative PCR methods [19,26,27]. The analysis of
plasma nuclear and mitochondrial DNA levels followed
our previous methods [18,19]. In brief, 5 ml of peripheral
venous blood in an EDTA-containing tube was collected
and the blood sample was centrifuged at 3000 rpm for 10
minutes. 400 µl of plasma sample extracted by a QIAamp
DNA Mini Blood Kit (No. 51304, Qiagen, Düsseldorf, Ger-
many) was used for each measurement. Primers of the
beta globulin gene (forward: 5’-GTG CAC CTG ACT
CCT GAG GAG A-3’; reverse: 5’-CCT TGA TAC CAA
CCT GCC CAG-3’) and ND2 gene (forward: 5’-CAC
AGA AGC TGC CAT CAA GTA-3’; reverse: 5’-CCG
GAG AGT ATA TTG TTG AAG AG-3’) were used, and
the concentration adjusted to 10 µM containing 0.2 µl of
each primer, 10 µl 2X SYBR Green PCR Fast Master Mix
(No. 4385612, Applied Biosystems, San Francisco, CA,
USA), 7.6 µl H2O and 2 µl plasma DNA sample. The mix-
ture was placed in a StepOnePlus real-time PCR system
(Applied Biosystems) for reaction following the standar-
dized PCR procedure for 40 cycles: 95 C for 20 seconds,
followed by 95 C for 3 seconds and 60 C for 30 seconds.
Quantification of the PCR results followed the Pfaffl
method[28].
Cognitive and behavior tests
All of the cognitive tests were performed during the inter-
ictal state as evidenced by the EEG recording before the
cognitive test. A clinical neuropsychologist blinded to the
patients’ clinical diagnosis performed the neuropsychologi-
cal tests which were chosen to assess memory, executive,
attention, and visuospatial functions [29-31]. Verbal and
visual episodic memory were assessed by a modified Cali-
fornia Verbal Learning Test-Mental Status [32] and the
Rey-Osterrieth Complex figure after a 10-minute delay.
Language screening included the 16-item Boston Naming
Test and 3-step comprehension and semantic verbal
fluency.
Visuo-spatial abilities were assessed by a modified Rey-
Osterrieth Complex Figure, pentagons, a transparent
cube copy, and by the number location test from the
Visual Object and Space Perception Battery. The ability
to perform five arithmetic calculations was assessed,
while frontal lobe function was assessed by digit forward
and backward span, design fluency, Stroop Interference
test, and the Modified Trails B test. Neuropsychiatric
inventory (NPI) was used to assess behavioral symptoms.
All of the tests were administered to both the patients
and the controls for a statistical comparison of non-
standardized tests.
MRI protocols and VBM
MRI was performed using a 3.0 Tesla scanner (Excite, GE
Medical System, Milwaukee, WI, USA) equipped with
echo-planar capability. Three-dimensional spoiled gradi-
ent-recalled acquisition in a steady state sequence was per-
formed with the following parameters: TR/TI = 8600 ms/
400 ms, FOV: 240 mm × 240 mm, slice thickness 1 mm.
VBM was processed using the SPM5 software package
(http://www.fil.ion.ucl.ac.uk/spm) with study specific tem-
plates [30]. All T1-weighted images were spatially normal-
ized into the standardized Montreal Neurological Institute
space using a 12-parameter affine transformation and
non-linear normalization. The study-specific template was
then smoothed with an 8 mm full-width at half-maximum
(FWHM) isotropic Gaussian kernel.
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The original images were warped to match the custo-
mized templates and re-sliced onto a voxel size of 1 × 1 ×
1 mm to minimize partial volume effects. The images were
segmented into gray, white, and cerebrospinal fluid (CSF)
compartments with intensity inhomogeneity correction,
modulated with Jacobian determinants to compensate for
volume changes in non-linear spatial normalization, and
smoothed with a 10 × 10 × 10 mm FWHM isotropic Gaus-
sian Kernel [33]. A general linear model was used to assess
statistical differences in GM.
Statistical analysis
Categorical variables were compared using the chi-square
test. Neuropsychiatric performances between the two
groups were analyzed by the Mann-Whitney U test with
Bonferroni correction. Partial correlation analysis between
duration of epilepsy and serum biomarker/neuropsycholo-
gical performances was performed with age being consid-
ered as a confounding factor. Multiple linear regression
analysis was used to examine the relationship between
GM atrophy and serum biomarkers levels. All statistical
analyses were performed using the SAS software package
(version 9.2, SAS Statistical Institute, Cary, NC, USA). A
p value < 0.01 was considered statistically significant.
For VBM analysis, a significance threshold was set at p <
0.001 and corrected for multiple comparisons across the
whole brain (false discovery rate) with an extended thresh-
old of 250 voxels and applied to the resulting t-statistic
maps of GM. To detect any correlation of clinical data
with GM atrophy, partial correlation analysis of GM parti-
tions was applied to the biomarkers adjusted for the effect
of age at a significance of p < 0.01, corrected for multiple
comparisons.
Results
Demographic data and clinical characteristics of the
patients with TLE
The age of the patient group was 37.1 ± 10.3 years, which
was not significantly different from the control group
(37.2 ± 10.2 years). Educational levels were not signifi-
cantly different between the patient group (11.5 ± 4.3
years) and the controls (12.2 ± 3.4 years). The age of onset
in the patient group was 18.8 ± 12.7 years and the dura-
tion of epilepsy was 18.9 ± 11.9 years. According to seizure
frequency defined above, 22 patients were classified as
Group 1 (0.8 ± 0.3 times per month), and 12 patients as
Group 2 (3.3 ± 0.9 times per month). Eight patients
received monotherapy, and the remaining 26 patients
received polytherapy including 19 patients with two AEDs
and 7 patients with 3 AEDs. Among the patients with epi-
leptic focus, 21 had left temporal origins, and 13 from the
right side. According to semiology, 9 patients experienced
complex partial seizures only, while the other 25 patients
had partial seizures with or without secondary generaliza-
tion. Two patients had one or more seizures despite being
treated with two consecutive first-line antiepileptic
medications.
Biomarkers and cognitive tests
Table 1 shows the results of biomarkers and cognitive
tests in patients with TLE and the control group. While
all of the five selected biomarkers were higher in the
patient group compared with the controls, only levels of
HSP70 and S100ßP reached statistical significance (p <
0.001). A comparison of biomarker levels between those
with initial left versus right epileptogenicity showed no
statistical significance.
In the selected cognitive tests, the short and long
delayed verbal memory, visual memory, speech and lan-
guage ability, executive function tests and digit forward
spans were all significantly lower in the patient group than
in the control group (all p < 0.01). There was no statistical
difference in NPI total score between the patients and the
controls.
Correlation study between biomarkers with cognitive
tests
In the patient group, the correlation between age and
duration of epilepsy was not significant (s = 0.313, p =
0.07). Decreased memory scores in the CVLT-MS late
registration (s = −0.276, p = 0.01) and early recall score
(s = −0.304, p = 0.007) were inversely associated with
serum HSP70 level. The level of plasma nuclear DNA
showed an inverse correlation with verbal fluency (s =
−0.297, p = 0.008). A positive correlation was found
between plasma nuclear DNA and Trail Making test com-
pletion time (s = 0.333, p = 0.003), however after enrolling
the duration of epilepsy as a covariate into the regression
model, the correlation was not significant.
GM atrophy and regional variability
When all TLE patients were compared with the controls,
wide brain regions on the striatum, frontal and temporal
lobes were significantly different (Table 2, Figure 1). In
addition to the involvement of the hippocampus and
parahippocampus (Figure 1A), regions with atrophy in
our TLE group included middle and inferior temporal
(Figure 1B), putamen and thalamus (Figure 1C) and sup-
plementary motor areas (Figure 1D).
Morphometric data with atrophic regions were extracted
from four representative regions (Figure 1) to investigate
the variability of voxel changes between the controls and
patients with TLE (Figure 2). From the fitted plots, voxel
variabilities from the right supplementary motor area (Fig-
ure 2A), right thalamus (Figure 2B) and left caudate
nucleus (Figure 2C) in the patient group were small, and
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the values were all smaller than the controls. In contrast,
the variability in the left hippocampus (Figure 2D) was
large in the TLE group, although the mean voxel value
was still smaller than the control group. Further, a higher
level of HSP70 was correlated with a lower ipsilateral hip-
pocampal volume after correcting for the effect of age in
the linear regression model (R square = 0.22, p = 0.007).
Clinical characteristics, biomarkers and
neuropsychological tests results between Group 1 and 2
The TLE group was further divided into two groups
according to seizure frequency as defined previously.
Comparisons between the two patient groups in terms of
biomarkers, neuropsychological performance and corre-
lation with duration of epilepsy are shown in Table 3.
Table 1 Biomarkers and neuropsychiatric performances between patients with temporal lobe
Controls (n = 34) TLE patients (n = 34)
Biomarkers
Heat shock protein 70 (μg/ml) 130.84 ± 61.1 194.5 ± 116.1**
Non-specific enolase (ng/ml) 9.43 ± 1.9 9.51 ± 1.9
S100ß protein (pg/ml) 70.52 ± 28.0 99.83 ± 45.7 **
Plasma nuclear DNA (ng/ml) 28.62 ± 2.5 29.19 ± 2.7
Plasma mitochondrial DNA (ng/ml) 21.33 ± 1.1 21.15 ± 1.0
Verbal Memory CVLT-MS (9)
T1 6.18 ± 1.1 5.18 ± 1.5**
T2 7.74 ± 1.1 7.36 ± 1.4
T3 8.24 ± 0.9 8.06 ± 1.2
T4 8.59 ± 0.7 8.15 ± 1.0
30 sec free recall 8.65 ± 0.7 7.67 ± 2.0**
10-min free recall 8.38 ± 1.2 7.18 ± 2.3**
10-min recognition 8.53 ± 0.9 7.55 ± 1.8
Visual Memory
Modified Rey-Osterrieth recall (17) 15 ± 2.5 11.64 ± 4.5**
Visuospatial Functions
Modified Rey-Osterrieth copy (17) 17 ± 0 16.79 ± 0.7
Cube copy (2) 1.82 ± 0.5 1.05 ± 0.9
Pentagon copy (1) 1 ± 0 0.82 ± 0.4
Visual object and space perception (10) 8.29 ± 2.0 8.64 ± 1.8
Speech and Language Ability
Semantic Fluency (1 minute)
Animal 21.59 ± 3.9 15.3 ± 5.4**
Fruit 15.75 ± 2.8 11.54 ± 3.4**
Transportation 13.83 ± 3.8 9.26 ± 2.1**
Town 24.28 ± 6.2 16.82 ± 6.2**
Boston naming test (16) 15.58 ± 0.8 14.36 ± 2.2**
Comprehension (4) 3.88 ± 0.3 3.51 ± 0.9
Abstract thinking (3) 2.58 ± 0.7 1.97 ± 1.2
Problem solving (3) 2.60 ± 0.7 2.00 ± 1.1
Executive function
Digit backward 5.0 ± 1.6 4.74 ±1.5
Stroop interference correct (1 minute) 54.1 ± 10.9 40.33 ± 14.6**
Design fluency 10.78 ± 3.0 8.56 ± 5.6*
Trail Making test time (< 120 seconds) 23.6 ± 11.6 47.8 ± 35.3**
Correct line in Trail Making (14) 13.13 ± 2.7 11.92 ± 3.5
Calculation (5) 4.75 ± 0.7 4.51 ± 0.8
Digit forward 8.40 ± 0.8 7.44 ± 1.4**
Neuropsychiatric inventory score 1.91 ± 6.6 2.84 ± 5.5
Values expressed as mean ± standard deviation.
Number in parenthesis following task name = maximal scores
**p < 0.01. *p < 0.05 between TLE patients and controls
TLE temporal lobe epilepsy; CVLT-MS California Verbal Learning Test-Mental Status
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Group 2 had significantly higher serum HSP70, NSE and
S100ßP levels as compared with Group 1 (all p < 0.01),
while the differences in plasma nuclear and mitochon-
drial DNA were not significant. Among the biomarkers,
only the level of HSP70 had a positive correlation with
duration of epilepsy (s = 0.413, p < 0.01).
In neuropsychological performances, there were no
significant differences between Group 1 and 2. However,
with regards to the duration of epilepsy, an inverse cor-
relation was found in pentagon copy and comprehen-
sion, while a positive correlation was found in Trail
Making test completion time (p < 0.01).
Discussion
The present study explored the clinical significance of
serum biomarkers in relation to epileptic characteristics,
cognitive performance and regions of GM atrophy pat-
terns in patients with TLE. There were three major find-
ings. First, the TLE group had higher serum levels of
HSP70 and S100ßP and lower cognitive test scores com-
pared with the controls. The serum levels of HSP70, NSE
and S100ßP were significantly higher in the TLE patients
defined by a higher seizure frequency (Group 2). Second,
the inverse relationship between serum HSP70 levels
with hippocampal GM partitions, memory dysfunction
and duration of epilepsy suggest that HSP70 can be trea-
ted as a stress marker in TLE. Third, although the high
variabilities in the hippocampal volume suggest the rela-
tively lateralized nature of TLE, the homogenous atrophic
patterns in regions beyond the epileptic origin (i.e. the
supplementary motor area, thalamus and striatum) sug-
gest more extensive structural damage in this epileptic
disorder.
We found higher HSP70 levels in patients with TLE as
compared with the controls. HSP70 belongs to the family
of heat shock proteins that is involved in normal cellular
homeostasis and survival by acting as a molecular chaper-
one [34]. It is a constitutive protein which is expressed
after cell stress [6]. The role of HSP70 in patients with epi-
lepsy is controversial. The induction of HSP70 in patients
with TLE may reflect the stress condition conveyed by epi-
leptic activities [17], however, a compensatory upregula-
tion for neuroprotection has also been proposed [35]. In
an animal model, overexpression of HSP70 due to status
epilepticus had a positive correlation with seizure intensity,
suggesting the role of HSP70 in reflecting the severity of
neuronal damage [15]. Overexpression of HSP70 has simi-
larly been observed in the hippocampal end folium neu-
rons in patients with TLE, suggesting a correlation with
the neuronal loss [16]. Although HSP70 expression in epi-
lepsy may suggest stress rather than neuroprotection [17],
induction of HSP70 in protecting hippocampal neurode-
generation via modulating endogenous glutamate expres-
sion has also been observed [35]. Therefore, the elevated
serum levels of HSP70 can only be considered as a stress
biomarker reflecting neuronal cell damage in the hippo-
campus, since an inverse relationship with memory test
scores and hippocampal volume was found in addition to
the elevation of HSP70 levels in patients with higher sei-
zure frequencies and longer duration of epilepsy.
Another serum biomarker in this study showing a higher
level in the patients with TLE as compared with the con-
trols was S100ßP. The S100ßP homodimer is a neurite
growth-promoting factor [36], and is widely used as a
parameter for glial activation and blood brain barrier dis-
ruption [37]. In human tissues from patients with TLE,
overexpression of S100ßP from astrocytes without a con-
current increase in glia fibrillary acidic protein suggests
the pathophysiology of astrocyte dysregulation in TLE
[13]. An elevated CSF level of S100ßP has been considered
as a site-specific marker in patients with intractable TLE
[38], also reflecting the severity of acute brain injury [39].
A significant elevation of serum S100ßP levels has been
reported recently in Han Chinese TLE patients as com-
pared to healthy controls, with a higher level especially in
female patients [12]. Whether or not S100ßP is a suitable
marker for epilepsy is still inconclusive. Some reports have
indicated no differences in serum levels of S100ßP
between patients with TLE and controls [11,40,41]. Taken
together with the results of our study in that S100ßP was
significantly higher in Group 2 patients, we suggest that
the serum concentration of S100ßP could be another use-
ful biomarker in patients with TLE for the evaluation of
seizure activity.
Table 2 Voxel-based morphometry of gray matter
atrophy analysis
Brain Regions x y z T value Z-score
Right thalamus 6 −20 8 4.27 4.02
Left thalamus −2 −18 6 3.94 3.74
Left fusiform −30 −38 −24 3.71 3.54
Right inferior temporal 58 −34 −24 3.11 3.00
Right fusiform 42 −16 −36 3.04 2.94
Right medial temporal 18 0 −36 2.95 2.85
Left caudate −14 14 12 2.89 2.80
Left hippocampus −18 −9 −20 2.84 2.76
Left putamen −18 14 −6 2.40 2.35
Right supplementary motor area 6 −6 56 2.83 2.75
Right hippocampus 20 −6.24 −20 2.30 2.30
Left supplementary motor area −4 −16 56 2.09 2.05
Right caudate nucleus 14 6 20 2.70 2.63
Left amygdala −22 −6 −22 2.67 2.60
Right putamen 20 14 −4 2.38 2.33
[x,y,z] refers to Montreal Neurological Institute coordinates. T values were
determined by dividing the estimated regression coefficient by its standard
error
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The release of NSE from damaged neurons resulting
from increased permeability of the blood brain barrier
following seizure has been proposed as a possible
mechanism [14]. In contrast with the uncertainties of
S100ßP in epilepsy [40], the serum level of NSE is consid-
ered to be a more reliable marker for reflecting a longer
duration of partial epilepsy [10]. Although elevated
serum NSE levels have been frequently reported in
patients with partial seizures or status epilepticus [11,14],
the relationship with TLE was not found in a literature
search. We did not detect a significant difference in NSE
level between the TLE group and controls, however we
did find higher serum NSE levels in the patients with a
higher seizure frequency. Nevertheless, its role in relation
to cognitive performance was not established in the pre-
sent study nor was the correlation with duration of epi-
lepsy in TLE patients. Compared with HSP70, the
elevated S100ßP and NSE levels found in this study could
be regarded as indirect evidence for blood brain barrier
disruption.
Relatively little is known about circulating plasma
nuclear and mitochondrial DNA in neurological diseases,
however, they are generally considered to be markers of
cell death in the form of necrosis or apoptosis [42]. The
elevated plasma nuclear and mitochondrial DNA levels
observed in critically ill patients [19] suggests a release of
extracellular DNA from necrotic cells. Our study failed
to detect differences either in plasma nuclear or mito-
chondrial DNA levels between the patients with TLE or
controls. The inverse correlation of plasma nuclear DNA
levels with executive function test may imply it is a neu-
ronal damage marker, however further studies are needed
to substantiate this explanation.
In TLE, there is a strong asymmetrical distribution of
temporal lobe abnormalities with respect to epileptogen-
esis, particularly in the hippocampus and also to a lesser
degree on the parahippocampal and entorhinal cortex
[23]. In the present study, patients with TLE showed high
lateralization of the epileptic focus from the initial EEG
recording with ipsilateral hippocampal atrophy based on
Figure 1 Voxel based morphometry revealed atrophy regions in the temporal lobes of epilepsy patients in a wide range of brain
areas as compared with the age-matched controls. A. Hippocampus and lateral temporal regions; B. Upper temporal and tail of the
hippocampus; C. Striatum and thalamus; D. Supplementary motor area. The anatomical reference = Montreal Neurological Institute Template.
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Figure 2 Variability of fitted data of brain atrophy in the controls and patients with temporal lobe epilepsy (TLE). (x,y,z) refers to
Montreal Neurological Institute coordinates.
Table 3 Relationship of clinical characteristics with biomarkers and neuropsychiatric performances in patients with
temporal lobe epilepsy
Seizure frequency Duration of epilepsy
Group 1 (n = 22) Group 2 (n = 12) s coefficient
Duration of epilepsy (years) 16.7 ± 8.5 20.3 ± 13.6 -
Number of antiepileptic drugs used Biomarkers 1.6 ± 0.6 2.52 ± 0.7 -0.029
Heat shock protein 70 (µg/ml) 123.4 ± 34.7 324.7 ± 97.4** 0.413†
Non-specific enolase (ng/ml) 8.4 ± 1.2 11.3 ± 1.13** 0.062
S100 ß protein (pg/ml) 79.04 ± 12.5 148.95 ± 43.6** 0.132
Plasma nuclear DNA (ng/ml) 29.22 ± 2.2 30.33 ± 2.2 0.18
Plasma mitochondrial DNA (ng/ml) 21.04 ± 1.0 21.13 ± 1.1 0.044
Verbal Memory CVLT-MS (9)
30 sec free recall 7.86 ± 1.5 7.27 ± 2.8 0.041
10-min free recall 7.23 ± 1.9 7.09 ± 2.9 0.045
10-min recognition 7.50 ± 2.0 7.64 ± 1.6 0.153
Modified Rey-Osterrieth recall (17) 16.77 ± 0.8 16.82 ± 0.6 0.3020
Cube copy (2) 0.91 ± 0.9 1.18 ± 0.9 -0.068
Pentagon copy (1) 0.82 ± 0.4 0.82 ± 0.4 -0.469†
Semantic fluency animal (1 minute) 14.09 ± 4.5 17.73 ± 6.6 -0.342
Boston naming test (16) 14.36 ± 2.3 14.18 ± 2.4 -0.175
Comprehension (4) 3.45 ± 0.9 3.45 ± 1.0 -0.631†
Abstract thinking (3) 1.95 ± 1.2 2.27 ± 1.2 -0.347
Problem solving (3) 2.00 ± 1.0 2.00 ± 1.18 0.107
Stroop interference correct (1 minute) 39.82 ± 16.5 42.64 ± 12.4 -0.374
Design fluency 7.68 ± 5.7 9.00 ± 5.8 -0.350
Trail Making test time (< 120 seconds) 51.68 ± 38.8 45.18 ± 32.1 0.548†
Digit forward 7.27 ± 1.5 7.73 ± 1.1 -0.346
Values expressed as mean ± SD or with correlation coefficient (s coefficient)
Neuropsychological tests listed above represent domains that were different from the control group; number in parenthesis following task name = maximal
scores
CVLT-MS California Verbal Learning Test-Mental Status
Group 1 = seizure frequency ≤ 2 times per month; Group 2 = seizure frequency > 2 times per month
** p < 0.01 compared with Group 1 and Group 2, †p < 0.01 in correlation analysis
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the morphometric data extracted from the hippocampus.
It is worth pointing out that the correlation study
between morphometric data with biomarkers was based
on a hierachical order. We did not perform the correla-
tion voxel-wisely to avoid the possibility of type I errors.
In contrast, in the extratemporal regions including the
thalamus, supplementary motor area and caudate
nucleus, the GM atrophy was relatively symmetric sug-
gestive of common pathways of epileptogenesis through
these structures. This observation may suggest the
importance of kindling effects from the epileptic focus
that either deactivate the inhibitory or stimulate the
excitatory pathways and induce progressive damage to
the related neuronal networks [34].
Although the study sample was small, we did not pool
the patients into one in terms of epileptic lateralization
for VBM analysis since the GM of the right and left cere-
bral hemispheres is asymmetric in healthy subjects, likely
reflecting underlying functional specificity. The patholo-
gic contribution from epilepsy to this asymmetry is sub-
stantially greater than normal underlying asymmetry.
Since the study results were used to correlate with cogni-
tive performances rather than tracing the epileptigenesis
circuit, a general GM atrophic pattern of these patients
was presented.
There are several limitations to this study. First, the
patients were only enrolled if they had not received an
operation for TLE, and we only selected patients without
a history of mental retardation or psychiatric comorbid-
ity. Whether the results of this study can only be applied
to this unique epilepsy syndrome or whether they can be
applied to the general population of epilepsy patients still
requires larger study cohorts for verification. Second,
long term AED therapy has been shown to contribute to
atherosclerosis and oxidative stress in epilepsy patients
[25]. As this study enrolled only a small number of
patients and as the use of AEDs was not the same among
all patients, the effects of the AEDs were therefore diffi-
cult to conclude. Different AEDs may have diverse
impacts on the selected serum biomarkers levels included
in this study. As such, interpretation of changes in bio-
markers in the patients should be treated with great care.
Lastly, the study design was mainly focused on the clini-
cal parameters and neuroimaging findings with relation
to the serum biomarkers during the interictal state.
Therefore, the observations here can not represent the
ictal pathogenesis of this disease model in relation with
these biomarkers.
Conclusions
The findings in the present study validated our initial
hypothesis that biomarkers in the circulation may show
predictive roles in the neuropsychological performance
and neuroimaging changes in TLE. Serum levels of
HSP70 had a positive correlation with the duration of
epilepsy, hippocampal atrophy and memory dysfunction,
suggesting that it can be used as a biomarker for stress-
related neuronal damage. Moreover, compared with
HSP70, the elevated S100ßP and NSE levels found in the
present study may be regarded as indirect evidence for
epileptic neuronal damage and blood brain barrier dis-
ruption. We are aware that the duration of epilepsy has
been regarded as an important factor leading to the wor-
sening of cognitive performance in patients with TLE [2]
and this was also shown in the study results. The concur-
rent frontal-subcortical GM atrophy in patients with TLE
reinforces the notion of a kindling phenomenon with
neuronal damage from the related temporal foci in this
highly lateralized epileptic disorder. A longitudinal study
might extend the repertoire for disease progression while
the evaluation in association with physiological para-
meters may unreveal the mechanism of epileptogenesis.
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